CD226/DNAM-1
Alpha Lifetech can provide CD226/DNAM-1 corresponding products, help each customer's research and development.
01
Introduction To CD226/DNAM-1
A drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD226/DNAM-1 protein is a common target in medicine.
CD226 is ubiquitously expressed in immune cells, including T cells, NK cells, and monocytes. CD226 is a transmembrane glycoprotein that consists of two immunoglobulin v-like domains (D1 and D2), a type I transmembrane domain, and an intracellular domain. The human intracellular domain contains two highly conserved phosphorylation sites, Y322 and S329 (corresponding to Y319 and S326 in the mouse homolog). The CD226 receptor is an important costimulatory receptor expressed by NK cells and CD8 T cells, and CD226 plays an important role in tumor immunity, mice deficient in CD226 have faster tumor growth than control mice. The primary ligand of CD226 is CD155, and the activity of the activated CD226 receptor is antagonized by three inhibitory receptors, TIGIT, CD96, and PVRIG.
Function of Target CD226/DNAM-1
CD226 is widely expressed in natural killer cells (NK cells), T cells, and other immune cells, and is involved in the regulation of immune-cell interactions through binding to its ligands CD112 and CD155. This interaction can enhance the activation, proliferation, and cytotoxicity of natural killer cells and T cells, and thus can play an important role in the immune response. CD226 also plays a key role in tumor immune surveillance. Compared with tumor cells overexpressing CD112 and CD155, tumor cells with lower CD226 expression were more likely to be recognized and killed by natural killer cells and T cells. CD226 is also involved in physiological processes such as the activation and agglutination of platelets, and these functions are important for maintaining the normal physiological state of the body.
Gene Pathway of Target CD226/DNAM-1
The CD226 signaling pathway has been extensively studied in NK cells. After binding by the corresponding ligands, CD226 localizes to lipid rafts and acts by binding to SAP 97, MAGUK, and the actin cytoskeleton. During the formation of immunological synapses, CD226 transmits an activation signal that subsequently induces the aggregation of LFA-1. Protein kinase C (PKC) phosphorylates CD226 at residue S326 to induce the linkage of LFA-1 to CD226. LFA-1 binds to ICAM-1 and promotes its conformational change, leading to the recruitment of Fyn and thus phosphorylates the Y319 residue of CD226. Phosphorylation at Y319 triggers the activation of ERK and AKT in NK cells and is essential for cytotoxicity in NK cells.
Fig 1: CD226 Gene Pathway. (Reference source: Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022 Apr;10(4):e004711. )
Alpha Lifetech Can Provide
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64592 | 50ug,100ug,500ug | |
| ALP64578 | 50ug,100ug,500ug | |
| ALP64577 | 50ug,100ug,500ug | |
Reference
[1] Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022 Apr;10(4):e004711.
[2] Conner M, Hance KW, Yadavilli S, Smothers J, Waight JD. Emergence of the CD226 Axis in Cancer Immunotherapy. Front Immunol. 2022 Jun 24;13:914406.
[3] Yeo J, Ko M, Lee DH, Park Y, Jin HS. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity. Pharmaceuticals (Basel). 2021 Feb 28;14(3):200.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102